Femasys Inc Ordinary Shares FEMY 深 滬
已收盤 08-01 16:00:00 美东时间
0.8196
-0.010
-1.16%
華盛通- 最 高0.8275
- 今 開0.82
- 成交量 13.63万股
- 最 低 0.80
- 昨 收 0.8292
- 總市值 2665.85万
- 52周最高 1.80
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.693
- 委 比 -66.67%
- 總股本 3252.62万
- 歷史最高 13.75
- 量 比 0.84
- 振 幅 3.32%
- 歷史最低 0.2479
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Femasys Faces Nasdaq Noncompliance Notice for Stock Price
Femasys ( ($FEMY) ) has provided an update. On July 16, 2025, Femasys Inc. rece...
07-19 05:50
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
Femasys, Inc. announced the regulatory approvals in Australia and New Zealand for its infertility solutions, FemaSeed and FemVue, expanding global access to innovative fertility treatments. FemaSeed, a next-generation insemination solution, offers higher pregnancy rates than traditional IUI, while FemVue provides a safe, ultrasound-based diagnostic for输卵管通畅性评估。这些批准体现了Femasys在解决女性健康关键问题方面的承诺，并为公司在全球市场增长提供了新的商业机会。
07-01 13:00
Femasys Approves Director Elections and Share Increase
The latest announcement is out from Femasys ( ($FEMY) ). On June 25, 2025, Fema...
06-26 04:40
Femasys Announces CE Mark Certification Under European Union Medical Device Regulation Of Class III FemBloc Blended Polymer Component
Femasys Inc., (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products,
06-25 21:07
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
Femasys Inc. announced the CE mark certification for the FemBloc® System, a non-surgical permanent contraceptive solution, under the EU Medical Device Regulation. This global first regulatory approval allows the system to be marketed in the European Economic Area. The FemBloc System, which uses a blended polymer to safely block fallopian tubes without surgery, offers a safer, more accessible, and cost-effective alternative to traditional steriliz...
06-25 13:00
Femasys Appoints Kelley Nicholas as Chief Commercial Officer
Femasys ( ($FEMY) ) has provided an update. On June 17, 2025, Femasys Inc. anno...
06-17 21:47
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
Femasys Inc. appointed Kelley Nicholas as Chief Commercial Officer (CCO) to lead the commercialization of its fertility products, particularly in the U.S. market, and expand global partnerships. With over 25 years of experience in driving revenue growth and leading commercial teams, Nicholas is expected to accelerate Femasys’ growth and strengthen its position in women’s health. Femasys has also granted her an incentive stock option to purchase 1...
06-17 13:00
美股大行评级 | GitLab遭多家大行下调目标价！Stifel首予优步"买入"评级，目标价110美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139839943846023169.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Loop Capital：维持Dave & Buster's Enter(PLAY)"买入"评级，目标价从35美元升至46美元</p> <p>• Stifel：维持嘉年华(CCL)"买入"评级，目标价从31美元升至
06-12 09:46
The Analyst Verdict: Femasys In The Eyes Of 6 Experts
6 analysts have expressed a variety of opinions on Femasys (NASDAQ:FEMY) over t...
06-12 04:01
Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations
Femasys, Inc., a leader in women's health innovations, has partnered with Carolinas Fertility Institute (CFI) to expand access to its FemaSeed® intratubal insemination product, offering a less invasive and cost-effective infertility treatment option. CEO Kathy Lee-Sepsick highlighted FemaSeed's growing momentum as a first-line fertility solution, while Dr. Tamer Yalcinkaya, Founder of CFI, emphasized the innovation's alignment with their mission ...
06-11 13:00
